Polysulfated Glycosaminoglycan in Dogs

Polysulfated glycosaminoglycan, often shortened to PSGAG, is an injectable prescription medication used in dogs with osteoarthritis and other non-infectious, degenerative, or traumatic joint disease. In the U.S., the best-known veterinary brand is Adequan Canine. It is different from pain relievers because it is classified as a disease-modifying osteoarthritis drug, meaning it is intended to support joint tissues as well as help control clinical signs. Dogs with arthritis may still need other therapies, but PSGAG is often used as one part of a broader mobility plan.

This medication is approved for intramuscular use in dogs. The FDA approval summary states it is indicated for the control of clinical signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints, and it is prescription-only because diagnosis and case selection require veterinary judgment. That matters because limping, stiffness, and reluctance to exercise can also be caused by cruciate ligament injury, hip dysplasia, neurologic disease, infection, or other orthopedic problems.

For many pet parents, the main appeal is that PSGAG is not a steroid and does not work the same way as an NSAID. Some dogs receive it early in arthritis care, while others start it after stiffness, slower rising, trouble with stairs, or reduced activity become more noticeable. Improvement is not always immediate. Some dogs respond within the loading series, while others need a few weeks before changes in comfort or mobility are easier to see.

PSGAG is usually most helpful when it is paired with other evidence-based options such as weight management, controlled exercise, home traction support, rehabilitation, and pain-control medications when needed. Cornell notes that canine osteoarthritis is progressive and usually managed with a multimodal approach rather than one treatment alone. Your vet can help decide whether PSGAG fits your dog’s age, diagnosis, bleeding risk, and overall treatment goals.

PSGAG is a semisynthetic glycosaminoglycan derived from bovine tracheal cartilage. Merck Veterinary Manual describes it as primarily containing chondroitin sulfate and notes that, after intramuscular injection, it is absorbed into the bloodstream and later incorporated into both healthy and damaged cartilage. In practical terms, the medication is meant to support the joint environment rather than only dull pain signals.

Its exact mechanism is not fully defined, but available veterinary references describe several likely effects. PSGAG appears to inhibit inflammatory mediators and cartilage-degrading enzymes, including metalloproteinases, elastase, and stromelysin. It also appears to increase synthesis of hyaluronic acid, proteoglycans, and collagen in vitro. Those actions may help protect cartilage, support joint fluid quality, and reduce the cycle of ongoing wear inside an arthritic joint.

VCA notes that the drug can accumulate in the joint within about two hours, but visible benefits may still take up to four weeks. That delay is important for expectations. A dog may not look dramatically better after the first injection, even when the medication is working as intended. Pet parents often notice gradual changes instead, such as easier rising, less stiffness after rest, or more willingness to walk and play.

Because osteoarthritis is progressive, PSGAG is usually used to help slow functional decline and improve day-to-day comfort, not to cure arthritis. Dogs with advanced disease may still need additional support, including NSAIDs, monthly monoclonal antibody therapy, rehabilitation, or treatment of the underlying orthopedic problem. Your vet can help match the plan to your dog’s stage of disease and household goals.

Side effects with polysulfated glycosaminoglycan are generally considered uncommon, and Merck notes that toxicity has been minimal when the drug is used appropriately. Even so, this is still a prescription injection, and dogs should be monitored for changes after each dose. Mild reactions reported in veterinary references include temporary pain at the injection site, diarrhea, vomiting, and reduced appetite.

A more important caution is bleeding risk. PSGAG is chemically similar to heparin, so overdose may inhibit normal clotting. Merck specifically warns that concurrent aspirin may prolong bleeding times, and PetMD notes that dogs with known or suspected bleeding disorders should not use the medication. Signs that need prompt veterinary attention include unusual bruising, nosebleeds, blood in stool, dark tarry stool, vomiting blood, or a large swelling at the injection site.

PetMD also advises caution in dogs with liver disease or kidney disease, especially if an overdose occurs. Safety has not been fully established in breeding, pregnant, or lactating dogs. If your dog has a history of low platelets, clotting problems, severe liver disease, or unexplained bleeding, tell your vet before the first injection so the plan can be adjusted.

See your vet immediately if your dog develops collapse, trouble breathing, facial swelling, severe vomiting, marked lethargy, or significant bleeding after an injection. Those signs are not expected routine effects and need urgent assessment. For milder issues, such as temporary soreness or stomach upset, contact your vet for next steps rather than stopping or restarting the medication on your own.

In dogs, the labeled dose is 2 mg per pound of body weight given by intramuscular injection twice weekly for up to four weeks, for a maximum of eight injections. That dosing appears in the FDA approval summary and in Merck Veterinary Manual. VCA also notes that the medication may be given twice weekly for up to four weeks, and that improvement may take several weeks to appreciate.

Most dogs receive the initial loading series first. After that, some vets repeat a series when arthritis signs return, while others tailor a maintenance schedule based on response, age, mobility goals, and any other medications in the plan. Long-term schedules vary by patient, so pet parents should not assume another dog’s protocol is right for theirs.

Many clinics give the injections in hospital, especially at the start. In some cases, your vet may teach you how to give intramuscular injections at home. If home treatment is part of the plan, ask for hands-on training, exact dose volume, needle size, storage instructions, and what to do if a dose is missed. PetMD notes that sterile technique matters, needles should not be reused, the vial stopper should be disinfected before use, and the vial should not be mixed with other drugs or solvents.

Do not change the dose, route, or schedule without veterinary guidance. A dog that is still limping may need a recheck rather than more frequent injections. Arthritis can worsen over time, but sudden lameness can also point to a new injury, infection, or another orthopedic problem. Your vet may recommend an exam, bloodwork, or imaging before continuing treatment.

The most important interaction concern is with medications or supplements that can affect clotting. Merck specifically notes that because PSGAG is chemically similar to heparin, overdose may inhibit coagulation and concurrent aspirin may prolong bleeding times. That means your vet should know about every product your dog receives, including aspirin, NSAIDs, fish oil, joint supplements, herbal products, and any drugs used around surgery or dental procedures.

PSGAG is often used alongside other arthritis therapies, but combination plans still need oversight. Cornell describes osteoarthritis care as multimodal, and many dogs receive NSAIDs, gabapentin, amantadine, rehabilitation, omega-3 fatty acids, or monthly injectable pain-control therapies as part of the same plan. These combinations can be appropriate, but they should be chosen case by case based on diagnosis, comfort level, liver and kidney status, and bleeding risk.

There is also a practical administration issue: PetMD advises not to mix Adequan Canine with other drugs or solvents in the same vial or syringe. If your dog receives multiple injectable medications, your vet will decide whether they should be separated by site, timing, or visit. That helps reduce contamination risk and avoids compatibility problems.

Before starting PSGAG, tell your vet if your dog has a bleeding disorder, low platelets, liver disease, kidney disease, a planned surgery, or a history of unusual bruising. Also mention any over-the-counter human pain relievers in the home. Human medications can be dangerous for dogs, and they should never be added to an arthritis plan unless your vet specifically instructs you to do so.